India Sickle Cell Anaemia Market Research Report Forecast to 2032

List of Tables

Market Overview

India Sickle Cell Anaemia Market is anticipated to register a healthy CAGR of 12.50% during the review period.

Sickle cell anemia is a genetic blood disorder characterized by the presence of abnormal hemoglobin that causes red blood cells to become rigid and sickle shaped. It happens due to a mutation on the sixth position of the beta chain of hemoglobin where glutamic acid amino acid gets converted into valine. The treatment procedure includes blood transfusions, medication, and bone marrow transplants.

The increased prevalence of sickle cell disease in India increases the demand for drug treatment, and growing government support and policies associated with sickle cell anemia in India are major factors driving the growth of the India sickle cell anemia market. However, the high cost of bone marrow transplants and the side effects associated with drug treatment are expected to restrain the growth of the Indian market. Nevertheless, the Indian government is forming partnerships with Indian manufacturers to produce affordable sickle cell disease medications, which is attributed to creating lucrative opportunities for the players operating in the Indian market.

Market Segmentation

Based on type, the India sickle cell anemia market has been segmented into sickle cell anemia, sickle hemoglobin-c disease (SC), sickle beta-plus thalassemia, and sickle beta-zero thalassemia.

Based on diagnosis &treatment, the market has been segmented into diagnosis, and treatment.

Major Players

The key market competitors are Cipla Inc, Novartis AG, United Biotech Pvt ltd., Pfizer Inc, Emmaus Medical, Inc, Neon, Celon Labs, and Teva Pharmaceutical Industries Ltd.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
- 3.5.1 Primary Research DATA FLOW:
- 3.5.2 Primary Research: Number of Interviews conducted
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
- 3.7.1 Data forecasting Technique
3.8 DATA MODELLING
- 3.8.1 microeconomic factor analysis:
- 3.8.2 Data MODELLING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 Growing Government Support and Policies associated with sickle cell anaemia in India
- 4.2.2 Increased prevalence of Sickle CELL among india Increases the demand for drug treatment
4.3 RESTRAINTS
- 4.3.1 High cost of bone marrow transplant and side effects associated with drug treatment
4.4 OPPORTUNITY
- 4.4.1 Indian government is forming partnerships with Indian manufacturers to produce affordable sickle cell disease medications

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 Threat of New Entrants
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 Threat of Substitutes
- 5.1.4 Bargaining Power of Buyers
- 5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON THE INDIA SICKLE CELL ANAEMIA MARKET

6 INDIA SICKLE CELL ANAEMIA MARKET, BY TYPE

6.1 OVERVIEW

7 INDIA SICKLE CELL ANAEMIA MARKET, BY DIAGNOSIS &TREATMENT

7.1 OVERVIEW

8 COMPETITIVE LANDSCAPE

8.1 INTRODUCTION
8.2 MARKET SHARE ANALYSIS,49
8.3 COMPETITOR DASHBOARD
8.4 PUBLIC PLAYERS STOCK SUMMARY
8.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
8.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 8.6.1 product approval

9 COMPANY PROFILES

9.1 CIPLA LTD
- 9.1.1 COMPANY OVERVIEW
- 9.1.2 FINANCIAL OVERVIEW
- 9.1.3 PRODUCTS OFFERED
- 9.1.4 KEY DEVELOPMENTS
- 9.1.5 SWOT ANALYSIS
- 9.1.6 KEY STRATEGIES
9.2 UNITED BIOTECH PVT LTD.
- 9.2.1 COMPANY OVERVIEW
- 9.2.2 FINANCIAL OVERVIEW
- 9.2.3 PRODUCTS OFFERED
- 9.2.4 KEY DEVELOPMENTS
- 9.2.5 KEY STRATEGIES
9.3 NEON
- 9.3.1 COMPANY OVERVIEW
- 9.3.2 FINANCIAL OVERVIEW
- 9.3.3 PRODUCTS OFFERED
- 9.3.4 KEY DEVELOPMENTS
- 9.3.5 KEY STRATEGIES
9.4 NOVARTIS AG
- 9.4.1 COMPANY OVERVIEW
- 9.4.2 FINANCIAL OVERVIEW
- 9.4.3 PRODUCTS OFFERED
- 9.4.4 KEY DEVELOPMENTS
- 9.4.5 SWOT ANALYSIS
- 9.4.6 KEY STRATEGIES
9.5 TAJ PHARMACEUTICALS LIMITED.
- 9.5.1 COMPANY OVERVIEW
- 9.5.2 FINANCIAL OVERVIEW
- 9.5.3 Products OFFERed
- 9.5.4 KEY DEVELOPMENTS
- 9.5.5 KEY STRATEGIES
9.6 CELON LABS
- 9.6.1 COMPANY OVERVIEW
- 9.6.2 FINANCIAL OVERVIEW
- 9.6.3 Products OFFERed
- 9.6.4 KEY DEVELOPMENTS
- 9.6.5 KEY STRATEGIES
9.7 SALIUS PHARMA PVT. LTD.
- 9.7.1 COMPANY OVERVIEW
- 9.7.2 FINANCIAL OVERVIEW
- 9.7.3 Products OFFERed
- 9.7.4 KEY DEVELOPMENTS
- 9.7.5 KEY STRATEGIES
9.8 PFIZER INC
- 9.8.1 COMPANY OVERVIEW
- 9.8.2 FINANCIAL OVERVIEW
- 9.8.3 productS OFFERED
- 9.8.4 KEY DEVELOPMENTS
- 9.8.5 SWOT ANALYSIS
- 9.8.6 KEY STRATEGIES
9.9 EMMAUS MEDICAL, INC
- 9.9.1 COMPANY OVERVIEW
- 9.9.2 FINANCIAL OVERVIEW
- 9.9.3 products OFFERED
- 9.9.4 KEY DEVELOPMENTS
- 9.9.5 SWOT ANALYSIS
- 9.9.6 KEY STRATEGIES
9.10 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 9.10.1 COMPANY OVERVIEW
- 9.10.2 FINANCIAL OVERVIEW
- 9.10.3 productS OFFERED
- 9.10.4 KEY DEVELOPMENTS
- 9.10.5 SWOT ANALYSIS
- 9.10.6 KEY STRATEGIES

10 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELLING FOR MARKET SHARE ASSESSMENT
TABLE 2 INDIA SICKLE CELL ANAEMIA MARKET, BY TYPE, 2019-2032 (USD MILLION)
TABLE 3 INDIA SICKLE CELL ANAEMIA MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD MILLION)
TABLE 4 INDIA SICKLE CELL ANAEMIA MARKET, BY TREATMENT, BY TYPE, 2019-2032 (USD MILLION)
TABLE 5 INDIA SICKLE CELL ANAEMIA MARKET, FOR PHARMACOTHERAPY, BY TYPE, 2019-2032 (USD MILLION)
TABLE 6 INDIA SICKLE CELL ANAEMIA MARKET, FOR DIAGNOISIS, BY TYPE, 2019-2032 (USD MILLION)
TABLE 7 INDIA SICKLE CELL ANAEMIA MARKET, FOR DIAGNOISIS, BY TYPE, 2019-2032 (UNITS)
TABLE 8 INDIA SICKLE CELL ANAEMIA MARKET, FOR INSTRUMENTS, BY TYPE, 2019-2032 (UNITS)
TABLE 9 INDIA SICKLE CELL ANAEMIA MARKET, FOR TEST KITS, BY TYPE, 2019-2032 (UNITS)
TABLE 10 PUBLIC PLAYERS STOCK SUMMARY
TABLE 11 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
TABLE 12 PRODUCT APPROVAL
TABLE 13 CIPLA LTD: PRODUCTS OFFERED
TABLE 14 UNITED BIOTECH PVT LTD: PRODCUTS OFFERED
TABLE 15 NEON: PRODUCTS OFFERED
TABLE 16 NOVARTIS AG: PRODUCTS OFFERED
TABLE 17 TAJ PHARMACEUTICALS LIMITED: PRODUCTS OFFERED
TABLE 18 CELON LABS: PRODUCTS OFFERED
TABLE 19 SALIUS PHARMA PVT. LTD.: PRODUCTS OFFERED
TABLE 20 PFIZER INC: PRODUCT OFFERED
TABLE 21 PFIZER INC: KEY DEVELOPMENTS
TABLE 22 EMMAUS MEDICAL, INC: PRODUCT OFFERED
TABLE 23 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERED

LIST OF FIGURES

FIGURE 1INDIA SICKLE CELL ANEMIA MARKET: STRUCTURE
FIGURE 2INDIA SICKLE CELL ANAEMIA MARKET REPORT: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
FIGURE 3DRIVER IMPACT ANALYSIS (2023-2032)
FIGURE 4RESTRAINT IMPACT ANALYSIS (2022-2032)
FIGURE 5PORTER'S FIVE FORCES ANALYSIS: INDIA SICKLE CELL ANAEMIA MARKET
FIGURE 6INDIA SICKLE CELL ANAEMIA MARKET, TYPE SEGMENT ATTRACTIVENESS, 2022-2032 (USD MILLION)
FIGURE 7INDIA SICKLE CELL ANAEMIA MARKET, BY TYPE, 2022 & 2032 (USD MILLION)
FIGURE 8INDIA SICKLE CELL ANAEMIA MARKET SHARE (%), BY TYPE, 2022
FIGURE 9INDIA SICKLE CELL ANAEMIA MARKET, DIAGNOSIS &TREATMENT SEGMENT ATTRACTIVENESS, 2022-2032 (USD MILLION)
FIGURE 10INDIA SICKLE CELL ANAEMIA MARKET, BY DIAGNOSIS &TREATMENT, 2022 & 2032 (USD MILLION)
FIGURE 11INDIA SICKLE CELL ANAEMIA MARKET SHARE (%), BY DIAGNOSIS & TREATMENT, 2022
FIGURE 12INDIA SICKLE CELL ANAEMIA MARKET PLAYERS: COMPETITIVE ANALSIS, 2022
FIGURE 13COMPETITOR DASHBOARD: INDIA SICKLE CELL ANAEMIA MARKET
FIGURE 14CIPLA LTD: FINANCIAL OVERVIEW
FIGURE 15CIPLA LTD: SWOT ANALYSIS
FIGURE 16NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17NOVARTIS AG: SWOT ANALYSIS
FIGURE 18PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19PFIZER INC: SWOT ANALYSIS
FIGURE 20EMMAUS MEDICAL, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21EMMAUS MEDICAL, INC: SWOT ANALYSIS
FIGURE 22TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS